Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0AYTGS)
| ADC Name |
PF-08046037
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
PF-08046037; SGN-PDL1iT
Click to Show/Hide
|
|||||
| Organization |
Pfizer (Originator) (Top20 MNC)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Antibody Name |
Anti-PD-L1 antibody
|
Antibody Info | ||||
| Antigen Name |
Programmed cell death 1 ligand 1 (PD-L1)
|
Antigen Info | ||||
| Payload Name |
Imidazoquinoline-based TLR7 agonist
|
Payload Info | ||||
| Payload Target |
Toll-like receptor 7 (TLR7)
|
Target Info | ||||
| Linker Name |
Mannosidase-cleavable maleimidopropionyl-mannose linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Pancreatic cancer | ||||
| Lung cancer | ||||
| Melanoma | ||||
| Head and neck cancer |